Get the App

Back Stocks profile

Stock analysis tool for investors

Biocon Ltd.

NSE: BIOCON | BSE:532523

₹304.55 -1.30 (-0.43%) 1D

Pharmaceuticals & Biotechnology

Buy Sell
View detailed Technical chart

Open an Account with Bigul in 5 minutes

Performance

Today’s low

302.80

Today’s High

310.40

52W low

217.50

52W High

321.20

Open Price

308.20

Prev. Close

267.4000

Volume

1237146.00

Value

376772814.30

Fundamentals

Market Cap Cr

36564.30

Price to Earnings

35.80

Price to Book Value

1.40

Dividend Yield

0.50

PE to Growth

0.30

Op Revenue TTM Cr

14755.70

Net Profit TTM Cr

1022.50

Cash From Operating Activity Cr

2953.90

Return on Equity %

5.16

EMA & SMA

Bullish Moving Averages

14

Bearish Moving Averages

2

5Day EMA

305.8

10Day EMA

304.3

12Day EMA

303.3

20Day EMA

298.5

26Day EMA

295.2

50Day EMA

286.2

100Day EMA

276.5

200Day EMA

268.4

5Day SMA

307.8

10Day SMA

304.5

20Day SMA

300.3

30Day SMA

290.1

50Day SMA

279.5

100Day SMA

276.3

150Day SMA

263.1

200Day SMA

263.1

DELIVERY AND VOLUME

DAILY AVG. DELIVERY VOLUME %

18 May, 2024

60.2

Week

35.3

Month

40

LEGEND

Positive Indicator

Neutral Indicator

Negative Indicator

RESISTANCE AND SUPPORT

305.93

PIVOT

First Resistance

309.07

Second Resistance

313.58

Third Resistance

316.72

First Support

301.42

Second Support

298.28

Third Support

293.77

Relative Strength Index

57.22

Money Flow Index

46.25

MACD

8.11

MACD Signal

8.68

Average True Range

11.39

Average Directional Index

35.56

Rate of Change (21)

13.98

Rate of Change (125)

32.93

Commodity Channel Index

48.6

Williams %R

-57.4

BETA

1 Month

0.75

3 Month

1.53

1 Year

0.98

3 Year

0.1

PRICE CHANGE ANALYSIS

↑ 0.18%

1 Week

Low

High

293.45

321.2

↑ 15.47%

1 Month

Low

High

259.85

321.2

↑ 6.17%

3 Months

Low

High

244.55

321.2

↑ 30.85%

6 Months

Low

High

231.25

321.2

↑ 24.08%

1 Year

Low

High

217.5

321.2

Indicator Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Graph
Total Qtr Revenue cr 571.50 611.30 588.30 549.20 570.70 614.90 588.40 490.30 578.50 509.70 405.30
Operating Expenses Qtr 480.40 491.50 451.50 441.20 550.70 517.90 461.70 439.10 491.20 438.70 388.00
Operating Profit Qtr 52.20 71.30 67.20 72.00 -44.00 37.10 27.80 2.60 26.50 34.30 -23.20
EBIDT Qtr Cr 91.10 119.80 131.60 127.70 1873.60 97.00 1135.90 51.20 87.30 71.00 17.30
Depreciation Qtr 29.80 30.90 30.60 29.80 29.40 29.10 29.80 28.60 28.10 27.60 26.50
Net Profit Qtr 14.00 24.00 34.70 46.60 1810.80 35.20 987.50 14.90 38.10 25.50 -6.60
Basic EPS Qtr 0.12 0.20 0.29 0.39 15.14 0.29 8.28 0.12 0.32 0.21 -0.06
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total Revenue Annual 2320.30 2264.30 1925.40 2178.60 2190.10
Operating Expenses Annual Cr 1864.60 1969.40 1677.10 1715.90 1702.40
Operating Profit Annual 262.70 23.50 61.10 312.50 286.00
Operating Profit Margin Annual % 11.32 1.04 3.17 14.34 13.06
Total Expenses Annual Cr 2184.50 2155.90 1785.70 1819.80 1801.60
EBIDT Annual Cr 455.70 294.90 248.30 462.70 487.70
EBIDT Annual margin % 19.64 13.02 12.90 21.24 22.27
Depreciation 121.10 116.90 108.20 103.50 98.00
PAT Before ExtraOrdinary Items Annual Cr 119.30 2848.40 86.10 280.50 436.30
Net Profit Annual 119.30 2848.40 86.10 280.50 440.90
Basic EPS Annual 1.00 23.87 0.72 2.36 3.72
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total ShareHolders Funds Annual 10912.30 10916.00 8092.90 7907.10 7537.30
Minority Interest Liability Annual Cr - - - - -
Total Non Current Liabilities Annual Cr 2164.70 1415.90 185.20 116.40 45.50
Total Current Liabilities Annual Cr 691.20 698.00 590.90 550.20 728.00
Total Capital Plus Liabilities Annual Cr 13768.20 13029.90 8869.00 8573.70 8310.80
Fixed Assets Annual 1518.00 1304.90 1155.10 977.30 945.10
Total Non Current Assets Annual 11008.20 10463.90 6466.80 6404.40 6227.10
Total Current Assets Annual 2760.00 2566.00 2402.20 2169.30 2083.70
Total Assets Annual 13768.20 13029.90 8869.00 8573.70 8310.80
Contingent Liabilities plus Commitments Annual Cr - 754.80 638.30 1749.60 2203.70
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Cash from Operating Activity Annual -123.20 219.30 47.60 478.40 387.10
Cash from Investing Activity Annual -296.40 -1177.80 -305.60 -618.30 -212.90
Cash from Financing Annual Activity 343.60 1039.40 112.00 27.80 -128.90
Net Cash Flow Annual - 80.90 -146.00 -112.10 45.30
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Book Value Per Share Annual 90.89 90.91 67.40 65.89 62.80
ROE Annual % 1.09 26.09 1.06 3.54 5.85
ROCE Annual % 2.55 1.44 1.69 4.47 5.13
Total Debt to Total Equity Annual 0.19 0.12 0.01 0.00 0.00
EBDIT Annual Margin % 21.42 14.79 14.28 22.81 24.52
Indicator Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Graph
Total Qtr Revenue cr 3965.70 4519.20 3620.20 3516.10 3928.80 3019.70 2384.20 2217.40 2476.10 2222.50 1945.30
Operating Expenses Qtr 3001.20 3026.90 2720.70 2708.20 2776.60 2296.80 1849.00 1740.10 1816.90 1686.00 1394.60
Operating Profit Qtr 915.90 926.80 741.60 714.40 997.30 644.30 470.70 399.40 591.90 488.20 445.80
EBIDT Qtr Cr 955.70 1513.50 875.50 807.90 1149.20 451.50 518.20 477.30 618.20 536.50 480.60
Depreciation Qtr 407.00 414.50 389.30 358.00 363.70 301.10 230.80 217.50 212.20 205.70 201.50
Net Profit Qtr 135.50 660.00 125.60 101.40 313.20 -41.80 46.90 144.40 238.60 187.10 138.30
Basic EPS Qtr 1.13 5.52 1.05 0.85 2.62 -0.35 0.39 1.21 2.00 1.57 1.16
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total Revenue Annual 15621.20 11550.10 8396.70 7360.30 6461.90
Operating Expenses Annual Cr 11457.00 8662.50 6213.80 5453.20 4697.40
Operating Profit Annual 3298.70 2511.70 1970.20 1652.60 1603.10
Operating Profit Margin Annual % 21.12 21.75 23.46 22.45 24.81
Total Expenses Annual Cr 14000.20 10194.60 7095.60 6226.00 5314.50
EBIDT Annual Cr 4164.20 2887.60 2182.90 1907.10 1764.50
EBIDT Annual margin % 26.66 25.00 26.00 25.91 27.31
Depreciation 1568.80 1113.10 814.20 715.10 552.20
PAT Before ExtraOrdinary Items Annual Cr 1382.00 810.00 978.50 925.40 899.80
Net Profit Annual 1022.50 462.70 648.40 740.50 748.20
Basic EPS Annual 8.55 3.87 5.42 6.19 6.30
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total ShareHolders Funds Annual 19783.70 17866.90 8432.50 7531.00 6705.80
Minority Interest Liability Annual Cr 5491.10 4621.90 1037.50 880.70 677.30
Total Non Current Liabilities Annual Cr 15437.10 21043.30 7096.00 5804.60 3052.70
Total Current Liabilities Annual Cr 15358.80 8510.70 3828.00 4210.10 4008.00
Total Capital Plus Liabilities Annual Cr 56070.70 52042.80 20394.00 18522.30 14443.80
Fixed Assets Annual 22264.50 20648.50 10653.00 9137.70 8140.70
Total Non Current Assets Annual 40891.50 39708.80 12011.70 10921.90 9118.80
Total Current Assets Annual 15179.20 12334.00 8382.30 7600.40 5325.00
Total Assets Annual 56070.70 52042.80 20394.00 18522.30 14443.80
Contingent Liabilities plus Commitments Annual Cr - 1990.90 1585.00 1588.60 1489.90
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Cash from Operating Activity Annual 2953.90 1852.50 1176.60 1159.70 1283.10
Cash from Investing Activity Annual -1004.50 -14281.80 -1699.10 -3624.70 -1558.90
Cash from Financing Annual Activity -2332.70 13048.70 242.10 2564.00 387.60
Net Cash Flow Annual - 619.40 -280.40 99.00 111.80
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Book Value Per Share Annual 210.52 187.31 78.87 70.09 61.52
ROE Annual % 5.16 2.58 7.69 9.83 11.15
ROCE Annual % 6.37 4.07 8.26 8.32 11.61
Total Debt to Total Equity Annual 0.80 0.99 0.58 0.47 0.28
EBDIT Annual Margin % 28.22 25.84 26.67 26.83 28.00
Name Holding Percent Holding Id Pledged % Locked %
Name Holding Percent Holding Id Pledged % Locked %
KIRAN MAZUMDAR SHAW 40.36 74802429 0 0
GLENTEC INTERNATIONAL 19.76 74802431 0 0
Name Holding Percent Holding Id
SBI CONTRA FUND 2.74 74802437
QUANT MUTUAL FUND - QUANT MOMENTUM FUND 1.24 74802438
LICI CHILD FORTUNE PLUS GROWTH FUND 4.41 74802440
Name Holding Percent Holding Id
ARUN SURESH CHANDAVARKAR 1.1 74802454
Ex-Date Dividend Amount Dividend Type Record Date Instrument Type
Jul 07, 2023 1.5 FINAL Jul 07, 2023 Equity Share
Jun 30, 2022 0.5 FINAL Jul 01, 2022 Equity Share
Jul 18, 2019 0.5 FINAL Jul 19, 2019 Equity Share
Jul 19, 2018 1 FINAL Jul 20, 2018 Equity Share
Jul 20, 2017 1 FINAL - Equity Share
Mar 17, 2016 5 INTERIM Mar 19, 2016 Equity Share
Apr 09, 2015 5 INTERIM Apr 10, 2015 Equity Share
Jul 10, 2014 5 FINAL - Equity Share
Jul 11, 2013 7.5 FINAL - Equity Share
Jul 05, 2012 5 FINAL - Equity Share
Jul 07, 2011 3 FINAL - Equity Share
May 05, 2011 1.5 INTERIM May 06, 2011 Equity Share
Jul 08, 2010 3.5 FINAL - Equity Share
Jul 13, 2009 3 FINAL - Equity Share
Jul 03, 2008 5 FINAL - Equity Share
Jun 28, 2007 3 FINAL - Equity Share
Jun 29, 2006 2.5 FINAL - Equity Share
Jun 29, 2005 2 FINAL - Equity Share
Jul 01, 2004 1 FINAL - Equity Share
Ex-Date Split Ratio Record Date
Ex-Date Purpose Notes
May 16, 2024 Audited Results & Final Dividend -
Feb 08, 2024 Quarterly Results -
Nov 10, 2023 Quarterly Results -
Aug 10, 2023 Quarterly Results -
May 23, 2023 Audited Results & Final Dividend -
Apr 26, 2023 Others To consider, Fund Raising.
Feb 14, 2023 Quarterly Results -
Nov 14, 2022 Quarterly Results -
Jul 27, 2022 Quarterly Results -
Apr 28, 2022 Audited Results & Dividend -
Jan 20, 2022 Quarterly Results -
Oct 21, 2021 Quarterly Results -
Jul 22, 2021 Quarterly Results -
Apr 28, 2021 Audited Results & Final Dividend -
Jan 21, 2021 Quarterly Results -
Oct 22, 2020 Quarterly Results -
Jul 23, 2020 Quarterly Results -
May 14, 2020 Audited Results -
Jan 23, 2020 Quarterly Results -
Oct 23, 2019 Quarterly Results -
Jul 25, 2019 Quarterly Results -
Apr 25, 2019 Audited Results, Dividend & Bonus -
Jan 24, 2019 Quarterly Results -
Oct 25, 2018 Quarterly Results -
Jul 26, 2018 Quarterly Results -
Apr 26, 2018 Audited Results & Final Dividend -
Jan 24, 2018 Quarterly Results -
Oct 26, 2017 Quarterly Results -
Jul 27, 2017 Quarterly Results -
Apr 27, 2017 Audited Results, F. Dividend & Bonus -
Jan 24, 2017 Quarterly Results -
Oct 20, 2016 Quarterly Results -
Jul 21, 2016 Quarterly Results & Others The Company will organize a conference call for analysts and investors on July 22, 2016.
Apr 26, 2016 Audited Results -
Mar 11, 2016 Interim Dividend -
Jan 21, 2016 Quarterly Results -
Oct 20, 2015 Quarterly Results -
Jul 23, 2015 Quarterly Results -
Apr 29, 2015 Audited Results -
Jan 22, 2015 Quarterly Results -
Oct 21, 2014 Quarterly Results -
Jul 24, 2014 Quarterly Results -
Apr 24, 2014 Audited Results & Dividend -
Jan 22, 2014 Quarterly Results -
Oct 24, 2013 Quarterly Results -
Jul 25, 2013 Quarterly Results -
Apr 25, 2013 Audited Results & Dividend -
Jan 24, 2013 Quarterly Results -
Oct 30, 2012 Quarterly Results -
Jul 25, 2012 Quarterly Results & Merger To Consider merger of Biocon Biopharmaceuticals Limited; a wholly owned subsidiary with the Company.
Apr 26, 2012 Audited Results & Dividend -
Jan 24, 2012 Quarterly Results -
Oct 19, 2011 Quarterly Results (Revised)
Jul 21, 2011 Quarterly Results -
Apr 28, 2011 Aud. Results, Dividend & Intm. Dividend -
Jan 20, 2011 Quarterly Results -
Oct 22, 2010 Quarterly Results -
Jul 23, 2010 Quarterly Results -
Apr 29, 2010 Audited Results & Dividend -
Jan 21, 2010 Quarterly Results -
Oct 22, 2009 Quarterly Results -
Jul 23, 2009 Quarterly Results -
Apr 28, 2009 Audited Results & Dividend -
Jan 21, 2009 Quarterly Results -
Jul 17, 2008 Quarterly Results -
Apr 22, 2008 Aud. Results, Dividend & Bonus Issue -
Jan 17, 2008 Quarterly Results -
Oct 18, 2007 Quarterly Results -
Jul 18, 2007 Quarterly Results -
Apr 19, 2007 Accounts & Dividend -
Jan 18, 2007 Quarterly Results -
Oct 18, 2006 Quarterly Results -
Jul 19, 2006 Quarterly Results -
Apr 20, 2006 Accounts & Dividend -
Jan 18, 2006 Quarterly Results -
Oct 19, 2005 Quarterly Results -
Jul 20, 2005 Quarterly Results -
Apr 20, 2005 Dividend & Accounts -
Jan 20, 2005 Quarterly Results -
Jul 14, 2004 Accounts -
May 14, 2004 Accounts & Dividend -
Ex-Date Bonus Ratio Record Date
Jun 12, 2019 1:1 2019-06-13
Jun 15, 2017 2:1 2017-06-17
Sep 11, 2008 1:1 2008-09-12
18 May 2024

Biocon Set For Strong Growth: CEO Shreehas Tambe

 Tambe attributed Biocon's success to a higher share in the US, Europe and emerging markets.
Bigul
17 May 2024

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Presentation and Video Recording
Bigul
17 May 2024

Q4FY24 Quarterly & FY24 Annual Result Announced for Biocon Ltd.

 Biotechnology company Biocon announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Biocon Q4FY24 reported consolidated revenue of Rs 3,966 crore with an EBITDA of Rs 964 crore. The net profit for Q4FY24, before exceptional items, stood at Rs 144 crore. Biocon Biologics' revenue for Q4FY24 was Rs 2,358 crore, marking an 18% growth. Research services through Syngene contributed Rs 917 crore to the revenue. Generics, including APIs and Generic Formulations, accounted for Rs 719 crore. FY24 Financial Highlights: FY24 revenue saw a significant 35% rise, reaching Rs 15,621 crore. FY24 EBITDA and Net profit grew by 44% and 31%, respectively, with Biosimilars revenue crossing USD 1 billion. Throughout FY24, Biosimilars produced a remarkable revenue of Rs 8,824 crore, witnessing a 58% increase. Research Services saw an annual revenue of Rs 3,489 crore. Generics marginally grew to Rs 2,799 crore for the financial year. The Board has recommended a final dividend of Rs 0.50 per share for FY24. Significant investment in R&D;, with net expenses accounting for 10% of revenue in FY24. Despite challenges in the U.S. biotech sector, Syngene's FY24 revenue incremented by 9%. Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics said, BIOCON GROUP “Q4FY24 performance was strongly led by Biologics that delivered the promised billion-dollar annual revenue milestone marking the successful transition of the Biosimilars acquisition from Viatris. Increased market shares of key products in the U.S., Europe and Emerging Markets coupled with significant volumes growth were the highlights of the Biosimilars business this quarter. With the recent approval of Liraglutide in the UK, we added to our list of 'global firsts' and demonstrated our capability in developing complex GLP-1 products which will be the key growth driver for the Generics business, going forward. Syngene is well positioned to benefit from the ‘China Plus One’ strategy which is being rapidly adopted by U.S. Pharma & Biotech companies. For the full year FY24, we reported consolidated revenue growth of 35% at Rs 15,621 crore and an EBITDA growth of 44 % at Rs 4,164 crore with healthy EBITDA margins of 27%. This growth was largely driven by Biosimilars which grew 58% to Rs 8,824 crore. The Biocon Group has strengthened business operations, expanded global reach and is now increasingly well positioned to deliver a new phase of growth spanning Biosimilars, GLP-1 peptides and CDMO services.” Siddharth Mittal, CEO & Managing Director, Biocon said, “We concluded FY24 with the Generics business posting a modest revenue growth. Generic Formulations reported a healthy 36% growth, as our products, particularly statins and immunosuppressants, gained traction across multiple geographies. This was offset by a degrowth in APIs on account of pricing pressure the business encountered, which impacted demand. Our preparations for entering the GLP-1 market opportunity is building momentum and we are pleased with the recent approval of Liraglutide in the UK, making Biocon the first generics Company to be approved for this product in an ICH or major regulated market. More importantly, the approval validates our scientific and development capability in bringing vertically integrated, complex peptide drug-device products to the market. This augurs well for us to capture GLP-1 opportunities that will drive our future growth. Our focus in FY25 will be directed towards launching new products and expanding our geographic reach through a direct presence and strategic partnerships. We will continue to focus on multiple cost improvement initiatives. We also intend to build upon our initial regulatory success in our peptide and GLP-1 focused pipeline in strategic markets." Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said, This has been a remarkable year for Biocon Biologics, as we evolved into a fully integrated global company with a presence in over 120 countries. We successfully integrated the acquired business 1 year ahead of plan, while ensuring business continuity and a seamless experience for our patients, customers, and partners. This is reflected in the numbers as our revenues crossed USD 1 billion for the full year with a healthy EBITDA margin, underpinned by a significant increase in market shares of our key products in the U.S., Europe, and Emerging Markets. Our R&D; pipeline too has progressed as planned and having secured market entry dates for 2 new products in U.S. and Canada, these products will serve to accelerate growth in the coming years. During the year, we reduced our acquisition debt. We also entered into a long-term strategic collaboration to distribute our products in India while retaining exclusive supply rights. FY24 has been a transformational year as we leverage our expanded global reach to address patient needs globally and unlock value for the benefit of all stakeholders." Result PDF
17 May 2024

Biocon Q4 Results Review - Biosimilar Off-Take, Lower R&D Spending Drive Earnings: Motilal Oswal

 Work-in-progress to improve business outlook across segments
Bigul
16 May 2024

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press Release on financial results for the quarter and year ended March 31, 2024.
Bigul
16 May 2024

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Change in Directorate

 The Board has approved the appointment of Mr. Atul Dhawan as an Additional Director (Non Executive and Independent) of the Company w.e.f. May 16, 2024.
Bigul
16 May 2024

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Date of payment of Dividend

 Date of payment of dividend
Bigul
16 May 2024

BIOCON LTD. - 532523 - Record Date For Final Dividend

 The Company has fixed July 05, 2024 as the record date for determining the entitlement of members to final dividend for FY 31.03.2024.
Bigul
16 May 2024

BIOCON LTD. - 532523 - Corporate Action-Board to consider Dividend

 The Board at its Board meeting held on May 16, 2024 has recommended final dividend of 10% i.e. Re. 0.50 per share
Bigul
16 May 2024

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Dividend Updates

 The Board recommended a final dividend at the rate of 10% i.e. Re. 0.50 per equity share, subject to the shareholders'' approval.
See all News

FAQs

The latest market price of Biocon Ltd. on NSE was Rs. 304.55 as of today.

The opening share price of Biocon Ltd. was Rs. 308.20 as of today.

The 52-week high share price of Biocon Ltd. was Rs. 321.20.

The 52 week low share price of Biocon Ltd. was Rs. 217.50.

Biocon Ltd. has a market cap of Rs. 36564.30 crore as of today. Please refer to the Fundamentals section for further details.

The PE ratio of Biocon Ltd. is 0.30. Please refer to the Fundamentals section for further details.

The operating revenue for Biocon Ltd. in the last FY was Rs.  14755.70 crore. Please refer to the Financials section for further details.

The Net Profit for Biocon Ltd. in the last FY was Rs. 1022.50 crore. Please refer to the Financials section for further details.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

The latest dividend declared by Biocon Ltd. was on 2023-07-07 for Rs. 1.5 per share. According to today’s share price, the dividend yield of Biocon Ltd. stands at 0.50. Please refer to the Corporate Actions section for further details.

The latest bonus issue declared by Biocon Ltd. was as of 2019-06-12. The bonus ratio declared in this issue was 1:1. Please refer to the Corporate Actions section for further details.

Please find Corporate actions section for more details.

Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.

Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.

Please refer to the News section for the latest news about Biocon Ltd..

Close

Let's Open Free Demat Account